This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
Excited to share MuSE 2 for accelerated (50x) mutation calling in cancer genomes: ~5min for WES and <1hr for WGS per tumor-normal pair. We set new standards in efficiency & accuracy by combining MuSE 2 and Strelka2 using a snakemake pipeline. See paper: https://t.co/zldewYk1zw
MD Anderson Leading edge in cancer research symposium last week was a blast! Thanks @WenyiWang4 and the meeting organizers for having me! So glad to catch up with old friends and make new ones!!
1/2 Bringing risk prediction models to clinics is challenging. We made a major progress by successfully validating our models on patients from real genetic counseling sessions where data collection takes <20min: https://t.co/wIEG9zHvpk.
Please check our new manuscript and the released somatic mutation caller MuSE 2.0 - it is ultra fast and very accurate for DNA-seq data from tumor samples.
Excited to announce that we have benchmarked MuSE2.0 for somatic mutation calling in computing time: finishing one pair of WGS sample < 1 hour, and in accuracy: achieves 99% recall of the PCAWG mutations. Check out our preprint: https://t.co/yg4o3UvQZF. 😊
Cancer survivor and #Swiftie Hallie Barnard has been paying it forward since she was 6 years old. This weekend, she will be receiving a generous gift herself: front row seats to the Taylor Swift concert.
Learn her story here: https://t.co/OTTj7Pj2b6 @KHOU#EndCancer
With @WenyiWang4 Lab we managed to #deconvolve even Korean bbq … at the #AACR23 check out their amazing posters tumor component-specific gene expression deconvolution rocks!
Understanding the evolution and ecology of cancer is difficult, but it can be very useful for an accurate prognosis. “Our solution uses one challenge (heterogeneity of the tumors) to solve the other,” says @WenyiWang4 at #AACR23. Learn more about her work: https://t.co/81W0PyFDoD
There will be >20 million cancer survivors in the US by 2026. To help characterize risks of this under-studied population, we developed a Bayesian semiparametric model for recurring events that are integrated with competing cancer outcomes. Check it out: https://t.co/q6uv0KtIS7
Very excited to share our paper in Nature Biotechnology today! Huge amount of work by @ShaolongCao@sxj307@JenniferWangMD et al! It is amazing to work with many experts across cancers. Every cancer tells its own story and our metric TmS can quantify it! https://t.co/7UiNTC745p
Very proud to release MuSE2.0 for somatic mutation calling, with ~50x speedup from MuSE1.0. It takes <10min to run WES data and 1hr to run WGS data from a tumor-normal pair. https://t.co/gp2dk1P0tR. Thanks to contributors: @mehrzadsamadi's team #Nvidia and Shuangxi Ji@sxj307!
We released CliP v1.2 today for fast subclonal reconstruction. With further optimization in computation, CliP finished running on ~9500 TCGA samples within 1 hour, and demonstrated accuracy within matched PCAWG samples. https://t.co/Qmu61n8C6c. Great job! @yujie_jiang679@sxj307